TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) - Analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for TriSalus Life Sciences in a report issued on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.36) for the year. The consensus estimate for TriSalus Life Sciences' current full-year earnings is ($1.55) per share.
A number of other brokerages also recently commented on TLSI. Canaccord Genuity Group reiterated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, March 28th. Lake Street Capital started coverage on shares of TriSalus Life Sciences in a research note on Thursday, February 13th. They set a "buy" rating and a $10.00 price objective for the company. Six research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $10.75.
View Our Latest Research Report on TriSalus Life Sciences
TriSalus Life Sciences Stock Down 5.6%
Shares of NASDAQ TLSI traded down $0.31 during mid-day trading on Tuesday, reaching $5.19. 34,602 shares of the company were exchanged, compared to its average volume of 42,291. TriSalus Life Sciences has a 1 year low of $3.50 and a 1 year high of $6.18. The firm has a 50-day moving average of $5.40 and a 200 day moving average of $5.16. The stock has a market cap of $196.38 million, a price-to-earnings ratio of -2.08 and a beta of 0.47.
TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last announced its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.13). The business had revenue of $9.17 million during the quarter, compared to analyst estimates of $9.04 million. During the same quarter in the previous year, the business earned ($0.60) earnings per share.
Insider Buying and Selling at TriSalus Life Sciences
In other news, insider Richard Marshak sold 6,597 shares of the business's stock in a transaction dated Monday, May 19th. The stock was sold at an average price of $5.18, for a total transaction of $34,172.46. Following the sale, the insider now owns 69,101 shares in the company, valued at approximately $357,943.18. The trade was a 8.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 16,125 shares of company stock worth $83,528. 27.50% of the stock is owned by insiders.
Institutional Trading of TriSalus Life Sciences
A number of institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. acquired a new position in TriSalus Life Sciences during the 1st quarter valued at approximately $55,000. Renaissance Technologies LLC purchased a new stake in shares of TriSalus Life Sciences during the fourth quarter valued at $67,000. Connective Capital Management LLC acquired a new position in shares of TriSalus Life Sciences in the fourth quarter valued at about $140,000. Northern Trust Corp raised its position in TriSalus Life Sciences by 22.7% during the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company's stock worth $161,000 after buying an additional 5,936 shares during the last quarter. Finally, Goldman Sachs Group Inc. acquired a new stake in TriSalus Life Sciences during the 1st quarter valued at approximately $187,000. 2.58% of the stock is currently owned by institutional investors and hedge funds.
TriSalus Life Sciences Company Profile
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
See Also
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
